vs
Axsome Therapeutics, Inc.（AXSM）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是Axsome Therapeutics, Inc.的1.6倍（$297.2M vs $191.2M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs -3.2%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs 3.0%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
AXSM vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.6倍
$191.2M
营收增速更快
AXSM
高出60.6%
-3.2%
两年增速更快
AXSM
近两年复合增速
3.0%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $191.2M | $297.2M |
| 净利润 | — | $14.6M |
| 毛利率 | — | 37.6% |
| 营业利润率 | -33.1% | 6.3% |
| 净利率 | — | 4.9% |
| 营收同比 | 57.4% | -3.2% |
| 净利润同比 | — | -23.9% |
| 每股收益（稀释后） | — | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMSCVL
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $297.2M | ||
| Q3 25 | $171.0M | $306.4M | ||
| Q2 25 | $150.0M | $277.7M | ||
| Q1 25 | $121.5M | $262.9M | ||
| Q4 24 | $118.8M | $306.9M | ||
| Q3 24 | $104.8M | $332.7M | ||
| Q2 24 | $87.2M | $300.4M |
净利润AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $14.6M | ||
| Q3 25 | $-47.2M | $19.2M | ||
| Q2 25 | $-48.0M | $9.3M | ||
| Q1 25 | $-59.4M | $14.7M | ||
| Q4 24 | $-74.9M | $19.2M | ||
| Q3 24 | $-64.6M | $22.6M | ||
| Q2 24 | $-79.3M | $17.3M |
毛利率AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 34.5% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 36.0% | ||
| Q3 24 | — | 36.1% | ||
| Q2 24 | — | 35.6% |
营业利润率AXSMSCVL
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 6.3% | ||
| Q3 25 | -27.0% | 8.2% | ||
| Q2 25 | -24.5% | 4.3% | ||
| Q1 25 | -46.9% | 5.3% | ||
| Q4 24 | -61.1% | 8.0% | ||
| Q3 24 | -59.8% | 9.0% | ||
| Q2 24 | -89.5% | 7.5% |
净利率AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 4.9% | ||
| Q3 25 | -27.6% | 6.3% | ||
| Q2 25 | -32.0% | 3.4% | ||
| Q1 25 | -48.9% | 5.6% | ||
| Q4 24 | -63.1% | 6.3% | ||
| Q3 24 | -61.7% | 6.8% | ||
| Q2 24 | -91.0% | 5.8% |
每股收益（稀释后）AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.53 | ||
| Q3 25 | $-0.94 | $0.70 | ||
| Q2 25 | $-0.97 | $0.34 | ||
| Q1 25 | $-1.22 | $0.53 | ||
| Q4 24 | $-1.54 | $0.70 | ||
| Q3 24 | $-1.34 | $0.82 | ||
| Q2 24 | $-1.67 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $305.1M | $107.7M |
| 总债务越低越好 | $70.0M | — |
| 股东权益账面价值 | — | $683.2M |
| 总资产 | $713.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMSCVL
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $107.7M | ||
| Q3 25 | $325.3M | $91.9M | ||
| Q2 25 | $303.0M | $93.0M | ||
| Q1 25 | $300.9M | $123.1M | ||
| Q4 24 | $315.4M | $91.1M | ||
| Q3 24 | $327.3M | $84.5M | ||
| Q2 24 | $315.7M | $69.5M |
总债务AXSMSCVL
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $683.2M | ||
| Q3 25 | $73.7M | $670.7M | ||
| Q2 25 | $73.1M | $653.6M | ||
| Q1 25 | $53.2M | $649.0M | ||
| Q4 24 | $57.0M | $635.7M | ||
| Q3 24 | $92.9M | $618.5M | ||
| Q2 24 | $102.9M | $597.8M |
总资产AXSMSCVL
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.2B | ||
| Q3 25 | $669.3M | $1.2B | ||
| Q2 25 | $639.8M | $1.1B | ||
| Q1 25 | $596.7M | $1.1B | ||
| Q4 24 | $568.5M | $1.1B | ||
| Q3 24 | $561.5M | $1.1B | ||
| Q2 24 | $548.2M | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $33.6M |
| 自由现金流经营现金流 - 资本支出 | — | $19.7M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.7% |
| 现金转化率经营现金流/净利润 | — | 2.30× |
| 过去12个月自由现金流最近4个季度 | — | $35.1M |
8季度趋势，按日历期对齐
经营现金流AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $33.6M | ||
| Q3 25 | $1.0M | $13.3M | ||
| Q2 25 | $-32.4M | $-9.6M | ||
| Q1 25 | $-43.4M | $44.5M | ||
| Q4 24 | $-26.2M | $17.3M | ||
| Q3 24 | $-18.6M | $23.7M | ||
| Q2 24 | $-30.1M | $17.1M |
自由现金流AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $19.7M | ||
| Q3 25 | $988.0K | $2.2M | ||
| Q2 25 | $-32.4M | $-23.0M | ||
| Q1 25 | $-43.7M | $36.2M | ||
| Q4 24 | $-26.2M | $8.3M | ||
| Q3 24 | $-18.7M | $18.2M | ||
| Q2 24 | $-30.2M | $6.9M |
自由现金流率AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 6.6% | ||
| Q3 25 | 0.6% | 0.7% | ||
| Q2 25 | -21.6% | -8.3% | ||
| Q1 25 | -36.0% | 13.8% | ||
| Q4 24 | -22.1% | 2.7% | ||
| Q3 24 | -17.9% | 5.5% | ||
| Q2 24 | -34.6% | 2.3% |
资本支出强度AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.7% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 0.3% | 3.2% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.1% | 1.7% | ||
| Q2 24 | 0.1% | 3.4% |
现金转化率AXSMSCVL
| Q1 26 | — | — | ||
| Q4 25 | — | 2.30× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 3.04× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
SCVL
暂无分部数据
